Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology, according to STAT. No financial terms or specific targets were disclosed in the announcement.
This move signals another large pharma company seeking external innovation in cancer drug discovery. For pharma and biotech leaders, this may mean more competition for partnerships and a shift in how oncology pipelines are built. Further information on the collaboration’s scope will be important for assessing its impact.